Walleye Capital LLC Invests $4.94 Million in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Walleye Capital LLC purchased a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 248,288 shares of the biopharmaceutical company’s stock, valued at approximately $4,936,000. Walleye Capital LLC owned about 0.21% of Catalyst Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC boosted its position in shares of Catalyst Pharmaceuticals by 62.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 681 shares during the period. nVerses Capital LLC purchased a new position in shares of Catalyst Pharmaceuticals during the 3rd quarter worth approximately $50,000. Larson Financial Group LLC boosted its position in shares of Catalyst Pharmaceuticals by 27,218.2% during the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 2,994 shares during the period. CWM LLC boosted its position in shares of Catalyst Pharmaceuticals by 686.5% during the 2nd quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 3,549 shares during the period. Finally, Meeder Asset Management Inc. purchased a new position in shares of Catalyst Pharmaceuticals during the 2nd quarter worth approximately $70,000. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Trading Down 1.2 %

Shares of CPRX stock opened at $22.07 on Monday. The firm has a fifty day moving average price of $21.26 and a 200 day moving average price of $18.79. The company has a market cap of $2.63 billion, a P/E ratio of 18.70, a PEG ratio of 3.40 and a beta of 0.75. Catalyst Pharmaceuticals, Inc. has a 12 month low of $13.00 and a 12 month high of $24.27.

Insider Buying and Selling

In related news, Director Molly Harper sold 17,500 shares of the business’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total transaction of $385,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Gary Ingenito sold 12,000 shares of the company’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $22.72, for a total transaction of $272,640.00. Following the completion of the transaction, the insider now owns 51,391 shares of the company’s stock, valued at $1,167,603.52. This represents a 18.93 % decrease in their position. The disclosure for this sale can be found here. Insiders own 11.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on CPRX shares. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, November 8th. Truist Financial raised their price target on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, November 11th. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 9th. Stephens initiated coverage on shares of Catalyst Pharmaceuticals in a research report on Monday, November 18th. They issued an “overweight” rating and a $35.00 price target for the company. Finally, Citigroup raised their price target on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $31.14.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.